Comparison between fixed-dose, intracoronary bolus-only versus standard weight-adjusted dose, intravenous bolus and infusion administration of abciximab in patients undergoing primary percutaneous coronary intervention.
| Title: | Comparison between fixed-dose, intracoronary bolus-only versus standard weight-adjusted dose, intravenous bolus and infusion administration of abciximab in patients undergoing primary percutaneous coronary intervention. |
|---|---|
| Authors: | Lee CH; National University Heart Centre, National University of Singapore, Singapore. Electronic address: mdclchr@nus.edu.sg.; Ngo HM; National University Heart Centre, National University of Singapore, Singapore.; Sewianto A; National University Heart Centre, National University of Singapore, Singapore.; Nguyen TH; National University Heart Centre, National University of Singapore, Singapore.; Lee J; National University Heart Centre, National University of Singapore, Singapore.; Teo SG; National University Heart Centre, National University of Singapore, Singapore.; Low AF; National University Heart Centre, National University of Singapore, Singapore.; Tan HC; National University Heart Centre, National University of Singapore, Singapore. |
| Source: | International journal of cardiology [Int J Cardiol] 2010 Nov 19; Vol. 145 (2), pp. 355-357. Date of Electronic Publication: 2010 Mar 15. |
| Publication Type: | Comparative Study; Letter; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8200291 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1874-1754 (Electronic) Linking ISSN: 01675273 NLM ISO Abbreviation: Int J Cardiol Subsets: MEDLINE |
| Imprint Name(s): | Publication: Amsterdam : Elsevier; Original Publication: Amsterdam : Elsevier/North-Holland Biomedical Press, c1981- |
| MeSH Terms: | Angioplasty, Balloon, Coronary/*methods ; Antibodies, Monoclonal/*administration & dosage ; Immunoglobulin Fab Fragments/*administration & dosage; Myocardial Infarction/physiopathology ; Myocardial Infarction/therapy ; Abciximab ; Adult ; Aged ; Female ; Follow-Up Studies ; Humans ; Infusions, Intra-Arterial ; Infusions, Intravenous ; Injections, Intra-Arterial ; Injections, Intravenous ; Male ; Middle Aged |
| Abstract: | We studied the safety and effectiveness of fixed-dose, intracoronary bolus-only abciximab in 195 patients who underwent primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. The patients were divided into 2 groups: Group A (n=120, 61.5%) received fixed-dose, intracoronary bolus-only, abciximab 10 mg; and Group B (n=75, 38.5%) received standard intravenous bolus (0.25 mg/kg) and maintenance abciximab infusion of 0.125 μg/kg/min for 12 h. There was no statistically significant difference in the baseline and post-procedure TIMI flow between Groups A and B. Final TIMI 3 flow was achieved in 90.0% and 89.3% of the patients in Groups A and B, respectively (p=0.14). Final TIMI myocardial perfusion grade 2/3 was achieved in 92.5% and 96.0% of the patients in Groups A and B, respectively (p=0.45). The six-month clinical outcomes were similar between Groups A and B (8.3% versus 5.3%, p=0.62).; (Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.) |
| Substance Nomenclature: | 0 (Antibodies, Monoclonal); 0 (Immunoglobulin Fab Fragments); X85G7936GV (Abciximab) |
| Entry Date(s): | Date Created: 20100316 Date Completed: 20111004 Latest Revision: 20181201 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.ijcard.2010.02.017 |
| PMID: | 20227778 |
| Database: | MEDLINE |
Comparative Study; Letter; Research Support, Non-U.S. Gov't